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Antibodies of the VRC01 class neutralize HIV-1,
arise in diverse HIV-1-infected donors, and are
potential templates for an effective HIV-1 vaccine.
However, the stochastic processes that generate
repertoires in each individual of >1012 antibodies
make elicitation of specific antibodies uncertain.
Here we determine the ontogeny of the VRC01 class
by crystallography and next-generation sequencing.
Despite antibody-sequence differences exceeding
50%, antibody-gp120 cocrystal structures reveal
VRC01-class recognition to be remarkably similar.
B cell transcripts indicate that VRC01-class anti-
bodies require few specific genetic elements, sug-
gesting that naive-B cells with VRC01-class features
are generated regularly by recombination. Virtually
all of these fail to mature, however, with only a
few—likely one—ancestor B cell expanding to
form a VRC01-class lineage in each donor. Develop-
mental similarities in multiple donors thus reveal the
generation of VRC01-class antibodies to be repro-
ducible in principle, thereby providing a framework
for attempts to elicit similar antibodies in the gen-
eral population.INTRODUCTION
Despite extraordinary global diversity and immune-evading
capabilities of HIV-1, the human immune system can develop
antibodies that neutralize HIV-1 effectively. After 2 years, roughly
20%of HIV-1-infected individuals develop antibodies capable of
neutralizing diverse strains of HIV-1 (Binley et al., 2008; Dhillon
et al., 2007; Li et al., 2007). From these HIV-1-infected donors,
a number of human monoclonal antibodies have been identified
that individually neutralize over 50% of circulating HIV-1 strains
(reviewed in Kwong and Mascola, 2012). Although such anti-
bodies might provide little benefit to the infected individuals in
whom they arise because of rapid escape by evolving virus
(Richman et al., 2003; Wei et al., 2003; Wu et al., 2012), they
nonetheless can prevent infection upon passive infusion or
genetic delivery in simian and murine transmission models (Ba-
lazs et al., 2012; Hessell et al., 2009; Mascola et al., 2000). Such
antibodies have thus been the focus of intense interest because
each provides a potential means to prevent HIV-1 infection.
Interest in effective HIV-1-neutralizing antibodies has focused
on mechanisms of recognition (epitope specificities and struc-
tural features that allow interaction with the envelope trimer)
and on B cell ontogeny (the origin and development of B cells
through processes by which their antibody genes recombine
and antigen-specific B cells mature to produce antibodies with
highaffinity immunologic recognition). Antibody specificity isImmunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc. 245
Table 1. Crystallographic Data Collection and Refinement Statistics
Complex Antibody
HIV-1 gp120
VRC-CH31d0219
93TH057
VRC-CH31d0219
93TH0573415v1
VRC-CH31d0219
93TH057KER2018_11
VRC01d45
KER2018_11
VRC01d45
ZM176.66
3BNC117d3
C1086
3BNC117d3
93TH0573415v1
VRC-PG20d23
93TH057
12A21d57
93TH057
PDB accession code 4LSP 4LSQ 4LSR 4LSS 4LST 4LSV 4JPV 4LSU 4JPW
Data collection
Space group P212121 P212121 P212121 P212121 P212121 I422 P212121 C121 P212121
Cell constants
a, b, c (A˚) a, b, g () 67.4, 84.0,
175.7 90.0,
90.0, 90.0
66.6, 67.7,
221.1 90.0,
90.0, 90.0
64.9, 67.7,
220.1 90.0,
90.0, 90.0
54.6, 65.3,
259.1 90.0,
90.0, 90.0
68.11, 77.98,
200.35 90.0,
90.0, 90.0
191.6 191.6,
104.0 90.0,
90.0, 90.0
68.6, 66.9,
231.6 90.0,
90.0, 90.0
164.3, 66.3,
95.1 90.0,
108.3, 90.0
62.0, 66.0,
213.0 90.0,
90.0, 90.0
Wavelength (A˚) 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Resolution (A˚) 50.00-2.15
(2.23-2.15)*
50.00-2.25
(2.29-2.25)
50.00-2.28
(2.32-2.28)
50.00-2.73
(2.79-2.73)
50.00-2.54
(2.54-2.50)
50.00-3.00
(3.05-3.00)
50.00-2.80
(2.85-2.80)
50.00-2.30
(2.34-2.30)
50.00-2.88
(2.93-2.88)
Rmerge 8.4 (51.9) 11.6 (52.2) 13.4 (60.2) 12.7 (62.8) 8.4 (33.7) 12.0 (33.3) 10.5 (62.1) 9.5 (39.3) 10.2 (48.4)
I / sI 18.1 (1.9) 17.0 (2.0) 10.4 (2.1) 13.8 (2.3) 13.3 (2.1) 24.8 (6.2) 14.1 (1.8) 20.0 (2.0) 11.0/2.0
Completeness (%) 95.8 (71.6) 98.6 (87.9) 90.7 (75.0) 90.6 (88.7) 89.5 (46.4) 99.1 (98.9) 98.4 (89.9) 90.7 (44.6) 97.8 (86.3)
Redundancy 5.7 (2.8) 5.5 (4.4) 5.1 (3.7) 6.8 (3.6) 3.7 (3.1) 7.3 (7.5) 4.1 (3.2) 3.2 (1.7) 3.6 (3.2)
Refinement
Resolution (A˚) 2.15 2.25 2.28 2.73 2.50 3.00 2.80 2.30 2.88
Unique reflections 52,604 47,596 41,144 27,290 33,762 18,566 27,017 39,655 71,104
Rwork / Rfree (%) 18.6/22.1 19.2/22.9 19.4/25.8 19.2/26.3 19.0/24.0 26.5/29.8 19.9/25.9 17.9/23.4 20.6/26.4
No. atoms
Protein 6175 6119 6082 6134 6175 6161 6120 6128 6144
Ligand/ion 76 18 15 37 0 5 27 36 15
Water 266 382 224 145 76 78 81 234 62
B-factors (A˚2)
Protein 63.8 57.9 76.5 46.5 140.4 86.6 46.5 78.2 64.0
Ligand/ion 75.4 75.5 94.6 57.0 - 64.7 75.5 70.3 57.2
Water 53.9 49.6 57.3 34.6 89.3 34.3 49.6 55.7 46.0
rmsds
Bond lengths (A˚) 0.004 0.008 0.005 0.005 0.004 0.002 0.004 0.008 0.002
Bond angles () 0.858 0.863 0.854 0.891 0.896 0.567 0.876 1.147 0.619
Ramachandran
Most favored
regions (%)
96.9 96.9 96.0 94.4 97.3 93.4 93.8 93.9 96.2
Additional allowed
regions (%)
2.7 3.0 3.3 4.7 2.4 5.8 4.9 5.8 3.6
Disallowed regions (%) 0.4 0.1 0.7 0.9 0.3 0.8 1.4 0.3 0.3
*Values in parentheses are for highest-resolution shell.
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Immunity
Ontogeny of VRC01-Class Antibodiesgained through V(D)J gene recombination to encode the naive B
cell receptor and through antigen-driven somatic mutation of
antibody genes to produce a clonal lineage of antibody-produc-
ing and memory B cells (Paul, 1999). These processes are highly
stochastic. The naive B cell repertoire in each individual is esti-
mated at 1012, and this repertoire is diversified further by somatic
mutation (Glanville et al., 2009; Paul, 1999). Highly effective HIV-
1-neutralizing antibodies, however, target just a few regions of
the viral spike and can employ similar structural modes. Anti-
bodies that recognize the same region, employ the same struc-
tural mode of recognition, and develop through similar B cell
ontogeny can be considered a ‘‘class’’ (Kwong and Mascola,
2012). Classes that are observed in multiple individuals poten-
tially represent immunological solutions to the challenge of
HIV-1 neutralization andmight be available to the general human
population.
Of the approximately 20 selected donors from whom highly
effective HIV-1-neutralizing antibodies have been identified
thus far, five have antibodies attributed to a single class (Scheid
et al., 2011; Wu et al., 2010, 2011). This class—the VRC01 class
named after the first identified classmember (Wu et al., 2010)—is
among the most effective thus far identified, with individual
members capable of neutralizing up to 90% of HIV-1 strains
at mean inhibitory (IC50) concentrations of approximately
0.1 mg/ml. Substantial characterization, both crystallographic
and with next-generation sequencing of antibody heavy-chain
transcripts, has been performed on two donors with VRC01-
class antibodies (NIAID 45 and IAVI 74), and additional charac-
terization, involving probe-based isolation of monoclonal anti-
bodies, has occurred with three other donors (RU 3, IAVI 57,
and CHAVI 0219) (Scheid et al., 2011; West et al., 2012; Wu
et al., 2011; Zhou et al., 2010). Antibodies of the VRC01 class
are characterized by a number of specific similarities including
heavy-chain mimicry of the CD4 receptor, a heavy chain derived
from the IGHV1-2 germline gene, and a light chain with a 5-amino
acid third complementary-determining region (CDR L3). Despite
this characterization, questions remain concerning the VRC01
class and its appropriateness as a vaccine template.
Antibodies of the VRC01 class show extraordinary degrees of
somatic mutation (Scheid et al., 2011; Wu et al., 2010, 2011),
sometimes reaching 30% of heavy-chain variable domain nucle-
otides. Even within the same donor, they are enormously
diverse, with variable domain amino-acid sequence differences
that exceed 50% (the approximate mean divergence between
unrelated antibodies) (Scheid et al., 2011; West et al., 2011,
2012; Zhou et al., 2010). How many B cell lineages generate
this diversity in each donor? How similar is VRC01-class recog-
nition and B cell ontogeny in different donors? And more gener-
ally, is elicitation sufficiently similar to allow for reelicitation of
VRC01-class antibodies in the general population? We sought
to answer these questions through a combination of antibody
identification, X-ray crystallography (to define recognition), and
next-generation sequencing (to provide genetic records). By
defining critical structural features and their corresponding
genetic signatures, we could delineate VRC01-class transcripts
in donor antibodyomes. Phylogeny-based analyses could then
be employed to define development pathways, and probabilistic
analyses—both frequentist and Bayesian—could be used to
delineate frequencies of recombination and to generalize, froma collection of donors, to characteristics of the overall class.
Altogether, our findings indicate VRC01-class antibodies in
diverse donors require relatively few genetic elements, evolve
remarkably similar recognition, and follow similar maturation
pathways to related structural solutions, suggesting that the elic-
itation of these important vaccine templates can in principle be
reproduced.
RESULTS
VRC01-Class Antibody with Vl-Derived Light Chain
One means of defining the ontogeny of an antibody class is to
identify antibodies of the class in many donors and then to use
these to enumerate class characteristics and pathways of devel-
opment. We and others have used probe-based methods to
identify VRC01-class antibodies, and the resurfaced stabilized
core 3 (RSC3) (Wu et al., 2010), a gp120 probe that selectively re-
tains the initial site of HIV-1 engagement with the CD4 receptor,
is a particularly discriminating probe. We used RSC3 to select
memory B cells from donor IAVI 23 of the Protocol G cohort
(Simek et al., 2009). Sequencing of RSC3-binding memory B
cells identified four antibodies, VRC-PG19, VRC-PG19b, VRC-
PG20, and VRC-PG20b, each of which potently neutralized
diverse strains of HIV-1 (see Figures S1A–S1E and Tables S1A
and S1B available online). To clarify the donor origin of each anti-
body, from this point forward we explicitly define the donor as a
subscript on each antibody name. All four of these new IAVI 23
antibodies appeared to be somatically related, with VRC-
PG19d23 and 19bd23 and VRC-PG20d23 and 20bd23 being most
closely related to each other. The heavy chains of these anti-
bodies derived from IGHV1-2, and their light chains contained
the 5-residue CDR L3 characteristic of the class (West et al.,
2012) (Figures S1F and S1G), suggesting that they were
VRC01-class antibodies. Notably, the light chains of VRC-
PG19d23, 19bd23, 20d23, and 20bd23 derived from a lambda pre-
cursor (IGLV2-14), in contrast to the kappa precursors reported
for all other previously identified VRC01-class antibodies
including VRC01d45 and VRC-PG04d74 (derived from IGKV3-20)
or VRC-CH31d0219, 3BNC117d3, and 12A21d57 (derived from
IGKV1-33) (Table S1C)(Scheid et al., 2011; West et al., 2012;
Wu et al., 2010, 2011). Thus whereas antibody identification is
a prerequisite to definition of the ontogeny of a class, additional
members of the class with unique properties continue to be
found. Nonetheless, once a substantial subset of a class has
been identified, these should allow essential properties that
allow effective HIV-1 neutralization by the class to be defined.
Structures of Diverse HIV-1 gp120 with VRC01-Class
Antibodies from Five Donors
Because similarity in recognition chemistry provides a funda-
mental means by which to define a class, we sought to answer
basic class questions by understanding how VRC01-class anti-
bodies recognize their viral target, the HIV-1 gp120 envelope
glycoprotein. All prior cocrystal structures of VRC01-class anti-
bodies were determined with the same core gp120 construct
(clade AE strain 93TH057) and from only two donors. We thus
sought to define the structures of antibodies from all known
donors with VRC01-class antibodies and with HIV-1 gp120s
from diverse genetic backgrounds (Table 1; Figure 1).Immunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc. 247
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Ontogeny of VRC01-Class AntibodiesTo define a collection of diverse HIV-1 gp120s for cocrystalli-
zation, we selected 15 gp120s with diverse Loop D and V5 re-
gions from five different clades (Table S1D). To assist crystalliza-
tion, we made chimeras of these 15 gp120s— swapping Loop D
and V5 regions—with the clade AE strain 93TH057 gp120 that
previously demonstrated robust crystallization (Wu et al., 2011;
Zhou et al., 2010). Crystallization trials of VRC01-class anti-
bodies in complexes with diverse gp120s or with chimeric-
93TH057 gp120s yielded a total of nine crystals suitable for
structural analysis (Table S1E). Crystallized gp120s were from
clades A, C, and AE and totaled six different gp120s, including
two chimeras. Crystallized antibodies were from five donors,
including 3BNC117d3 from donor Rockefeller University 3
(RU3), VRC-PG20d23 from donor IAVI 23, VRC01d45 from donor
NIAID 45, 12A21d57 from donor IAVI 57 (also called Rockefeller
University Patient 12), and VRC-CH31d0219 from donor CHAVI
0219. Diffraction data were collected, and structures solved by
molecular replacement and refined at resolutions limits of
2.15 A˚ to 3.0 A˚ (Table 1).
Structures of HIV-1 gp120 from clades A, C, and AE in com-
plexes with VRC01-class antibodies from five different donors,
each infected with a different strain of HIV-1 (Table S1F), showed
remarkable similarity (Figure 1; Figure S1H–S1L). When gp120s
were superimposed, the antibody-variable regions of the heavy
chains aligned closely (Ca-rmsd of 1.4 A˚), especially in the
CDR H2 region (Ca-rmsd of 0.7 A˚), which interacts with the
CD4-binding loop of gp120. Relative to CD4, the heavy chains
in the nine structures converged to within 2 A˚, likely reflecting
conserved hydrogen-bonding requirements (Figure 1B); salt
bridges between heavy chain residue Arg71HC andHIV-1 residue
Asp368gp120 were also preserved (Figure S1M). (Kabat
numbering [Kabat et al., 1991] is used to define CDR and frame-
work regions and numbering of antibody residues, with sub-
scripts of ‘‘LC’’ or ‘‘HC’’ denoting light chain or heavy chain,
respectively.) The antibody-variable regions of the light chains
were less well aligned (Ca-rmsd of 1.7 A˚) by the gp120 super-
position, except for the CDRL3 (Ca-rmsd of 0.18 A˚). Examination
of light chains positioned by superposition of the heavy chains
indicated radial divergence from the heavy-light interface, sug-
gesting that the interface interaction might constrain structural
variation of the antibody-variable region (Figure 1C). Overall,
the cocrystal structures allow for a precise definition of the
epitope boundaries (Figure S1N) and molecular variance for
the VRC01 class of HIV-1 neutralizing antibodies. When
compared with other classes of neutralizing antibodies such as
the VH1-69-derived stem antibodies against influenza virus
(Lingwood et al., 2012) or the VH1-69-derived CD4-induced an-
tibodies against HIV-1 (Huang et al., 2004), antibodies of the
VRC01 class showed substantially greater structural similarity
(Figure 2) (p < 0.001). Thus, although class recognition is
observed by several antibodies, antibodies of the VRC01 class
are unusual in their degree of similarity.
Light-Chain Recognition of HIV-1 gp120 by the VRC01
Class of Antibodies
By quantifying structural similarities, we reasoned that we
could identify critical recognition features, and—based on
these—derive genetic signatures that could be used to interro-
gate VRC01-class transcripts in donor antibodyomes. Heavy248 Immunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc.chains recognize the highly conserved initial site of CD4-
attachment, and it was thus possible to identify critical features
and a genetic signature (evolutionary similarity as revealed
through phylogenetic analysis), from analyses with a single
variant of HIV-1 gp120 (West et al., 2012; Wu et al., 2011;
Zhou et al., 2010). Light chains, however, protrude beyond
the initial site of CD4 engagement and contributed one third
of the buried interface between antibody and HIV-1 gp120 (Fig-
ure S2A, Table S1F). Roughly half of this recognition occurs in
the Loop D region and the other half occurs in the V5 region
(Figure S2A). To determine the structural basis for light-chain
recognition of diverse gp120s, we analyzed the sites of light-
chain interaction in the nine new structures (Figure S2). In these
nine structures, diverse surface shapes and chemistries were
observed for the light-chain-recognized region of gp120 (Fig-
ures S2B and S2C). Light chains of the VRC01 class accom-
modated this diversity with distinct CDR L1s and conserved
CDR L3s (Figure 3).
The CDR L1 varies considerably in sequence, length, and po-
sition (Figure 3A). IGKV3-, IGKV1-, and IGLV2-derived anti-
bodies, such as VRC01d45, 3BNC117d3, and VRC-PG20d23,
have CDR L1s of only six or seven residues in length, the result
of deletion during somatic maturation (Figure 3A). These dele-
tions (of two to six amino acids) shorten CDR L1, avoiding a
potential clash with Loop D (Figure 3B). By contrast, other
IGKV1-derived antibodies, such as VRC-CH31d0219 and
12A21d57, do not have deletions in CDR L1 (Figure 3C). These
two antibodies display identical somatic alterations to glycine
and adopt similar noncanonical conformations that swing their
CDR L1 regions away from Loop D (Figure 3D). Overall, despite
providing a substantial portion of the binding interface between
light chain and gp120, CDR L1 does not recognize Loop D as
much as avoid it, either through deletion or flexibility, both of
which exhibit precise structural solutions (Figure 3E) and both
of which are acquired through processes of somatic mutation.
In contrast to CDR L1 variation, the CDR L3 of VRC01-class
antibodies is constrained to 5-amino acids (corresponding to
Kabat numbered [Kabat et al., 1991] residues 89, 90, 91, 96,
and 97) with preference for a hydrophobic residue 91LC and a
Glu at residue 96LC (Figure 3F) (West et al., 2012). Analysis of
the structures of CDR L3 with diverse gp120s (Figure 3G) indi-
cated the packing of hydrophobic 91LC against the backbone
of Loop D and the interaction of Glu96LC with an electropositive
patch at the conserved base of V5. Mutational substitution of
residue 91 to Ala indicated that the packing of Loop D with the
signature ‘‘hydrophobic91LC’’ substantially contributes to anti-
body affinity (Figure 3H). In eight of the nine structures that we
determined, Glu96LC made a conserved hydrogen bond to the
backbone amide of Gly459gp120 at the N terminus of the V5 re-
gion (Figure S2D). With antibody 12A21d57, in which residue
96LC is a Gln, the distance between side chain and amide back-
bone was too great for hydrogen bonding (4.2 A˚) (Figure S2D),
and the interacting V5 region was not uniformly electropositive
(Figure S2E, top row). To quantify the impact of recognition by
the Glu96LC signature residue, we measured changes in affinity
with Glu or Gln substitutions (Figure 3I; Figure S2F). When
Gln was substituted for Glu, the affinity decreased by
10-fold, but when Glu was substituted for Gln, the affinity
was essentially unchanged. Perhaps relevant to this, a somatic
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Figure 1. VRC01-Class Recognition of HIV-1 gp120
(A) Nine cocrystal structures of five VRC01-class antibodies from five donors in complex with HIV-1 gp120s from clades A, C, and AE. Macromolecules are
shown in ribbon representation after alignment of gp120, which is shown in gray with CD4-binding loop (yellow), loop D (orange), and V5 (magenta) highlighted.
Antibody light chains are colored light blue, and heavy chains are shown in pale green with CDR H2 (green), CDR L1 (blue), and CDR L3 (cyan) highlighted.
(B) Class convergence of heavy chains. Upper panel shows interaction between CD4-binding loop of gp120 (yellow) and CDRH2s of VRC01 class (green) or C’C’’
ridge of CD4 (orange) with key interacting hydrogen bonds and salt bridges displayed as dotted lines. Lower panel shows mimicry of CD4 by VRC01 class-heavy
chains. Rotation (vertical axis) and translation (horizontal axis) relative to CD4 are displayed for each antibody, with the nine new structures colored different hues
of green according to the donor from which they were derived (and gray for previously published structures).
(C) VRC01-class variation of light chain relative to heavy chain. Light-chain-variable domain (VL) pivots around an axis that is close to both the CDR L3 and the
interface between heavy and light chains. Other regions such as CDR L1 have larger degrees of structural variance. Upper panel shows light-chain positional
variation displayed structurally. VL in worm representation is colored to distinguish CDR and framework regions, with worm thickness corresponding to the per-
residue variance in Ca position. Heavy-chain variable domain (VH, cartoon) and gp120 (surface) are shown for reference, colored the same as in (A). Lower panel
shows the average distance of each light-chain CDR (square) and framework (round) region relative to the centroid of the VH (horizontal axis) is plotted related to
the rmsd of the nine VRC01-class antibodies (vertical axis). The symbols and labels of CDR and framework regions are colored to match the worm colors in the
upper panel. See also Figure S1 and Table S1.
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Figure 2. VRC01 Class Exhibits Greater
Structural Convergence Than Other Anti-
body Classes
(A) Recognition by VH1-2-derived VRC01 class
antibodies. Upper panel is shown in the same
orientation as in Figure 1A with antigen gp120
depicted in gray surface and variable domains of
nine VRC01 class antibodies from five donors
displayed in cartoon (VH in pale green and VL in
slate blue).
(B) Recognition by VH1-69-derived anti-HIV-1
CD4i antibodies 17b (PDB ID 1RZK), 412d (PDB ID
2QAD), and X5 (PDB ID 2B4C).
(C) Recognition by VH1-69-derived influenza stem
antibodies CR6261 (PDB ID 3GBM), CR9114 (PDB
ID 4FQI), and F10 (PDB ID 3FKU). In both (B) and
(C), to allow comparisons between class mem-
bers, the VH of one member of each class was first
aligned with the VH region of VRC01 in (A) to pro-
vide a standard frame of reference. VRC01, 17b,
and CR6261 were used to represent their
respective classes. Other members of each class
were then aligned by superposition of their bound
antigen. Antigens are shown in gray, and anti-
bodies are shown in pale green (VH) and blue (VL).
Lower panels of (A), (B), and (C) are 90-degree
views from upper panels, looking down onto the
epitope from the antibody.
(D) Intraclass positional variation of VH domains are
shownwith average rotation angles and translation
distances between antigen-superposed class
members. VRC01 class show significantly lower
positional variation compared to the other antibody
classes. Data are represented as mean ± SEM.
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Ontogeny of VRC01-Class Antibodiesvariant of 12A21d57 named 12A12d57 contains a Glu at 96LC
(Scheid et al., 2011). Altogether, structural analysis identifies
two signatures: a CDR L1 signature with deletion, or mutation
to glycine, of two residues; a CDR L3 signature of 5-amino acids
with hydrophobic91LC at position 3 and Glu or Gln96LC at
position 4.
Genetic Record of Recombination and Maturation for
the VRC01 Class
To study the processes of recombination and maturation that
generate critical features of VRC01-class antibody light chains,
we performed next-generation sequencing and bioinformatics
analysis of light-chain-antibody transcripts from peripheral
blood mononuclear cells (PBMCs) of donors RU3, IAVI 23, NIAID
45, IAVI 57, and IAVI 74 (Table S2A). We interrogated time points
that were previously used to isolate antibodies 3BNC117dRU3,
VRC-PG20d23, VRC01d45, VRC03d45, 12A12d57, 12A21d57, and
VRC-PG04d74, respectively, from these donors. On identity-di-
versity plots (Figure 4A, top row), which resolves antibodyome
transcripts in two dimensions: identity to a known antibody
and divergence from germline V-gene, distinct islands of high
diversity and >90% identity to the template antibodies were
observed (Figure 4A, top row). None of the reads, however,
showed great than 85% identity to isolated antibodies from other
donors (Figures S3A–S3E), illustrating a high level of sequence
diversity for light chains of the VRC01 class.
To identify light chains of the VRC01 class, we used a criterion
of 5-amino acid CDR L3 length as a partial signature because it is250 Immunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc.present in all previously identified VRC01-class antibodies but in
only 1% of general human antibodies (West et al., 2012). We
further restricted our analysis to light chains of the same as-
signed germline IgVK or IGVL gene as the template antibody.
In addition, we chose those transcripts that displayed greater
than 15% nucleotide divergence from germline V-gene because
we expected VRC01-class antibodies to have a substantial de-
gree of somatic mutation (Wu et al., 2011). This analysis identi-
fied just a few sequences in donor IAVI 23, hundreds in donors
RU3 and IAVI 57, and thousands in donors IAVI 74 and NIAID
45. The CDR L3s of these sequences showed remarkable simi-
larity, within each donor and between donors, with the frequency
of residue usage for each position of the CDR L3 clearly
nonrandom, suggesting a specific signature (Figure 4A, middle
row). To confirm functionality of these identified sequences, we
synthesized diverse sequences from donors IAVI 57 and IAVI
74, reconstituted with the heavy chains from each of these do-
nors, and confirmed HIV-1 neutralization (Tables S2B and
S2C). A combined ‘‘mature CDR L3 genetic signature’’—defined
from the five donors and based on observed amino acid fre-
quencies of >20% for each CDR L3 position—was (CDR L3 po-
sition 1) residue 89LC Q, N, or A, (position 2) residue 90LC Q, V, A,
or S (position 3), residue 91LC F, L, or Y, (position 4) residue 96LC
E, and (position 5) residue 97LC F, G, or S. We applied this
genetic signature to all transcripts (Figure 4A, bottom row).
Notably, the mature genetic CDR L3 signature was absent in
light-chain transcripts of less than 5% germline divergence in
all donors, except donors RU3 and IAVI 74 (Figure 4A, bottom
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Figure 3. Structural Signatures in CDR L1 and CDR L3
(A) CDR L1 sequences for VRC01-class antibodies that avoid loop D through deletion, with germline genes italicized and bold, current structures in green text
(donor in blue subscript), and structures published elsewhere italicized.
(B) Complex structures for VRC01-class antibodies with CDR L1 deletions. Antibodies are shown in ribbon representation and gp120 with a semitransparent
surface, both colored the same as in Figure 1A.
(C) CDR L1 sequences for VRC01-class antibodies that avoid loop D through mutation to glycine. Sequence highlighting scheme is the same as in (A).
(D) Complex structures for VRC01-class antibodies with CDR L1 mutations to glycine. Antibodies are shown in ribbon representation and gp120 with a semi-
transparent surface, both colored the same as in (B).
(E) Rotation of light chains (vertical axis) for VRC01-class antibodies that use deletion (left) and glycine (right) mechanisms of CDR L1 avoidance. Rotations
calculated after gp120 superposition relative to the light chain of the 2010 VRC01-93TH057 gp120 complex structure. Data are represented as mean ± SEM.
(F) CDR L3 sequences. In Kabat numbering, the third position of the CDR L3 is defined as residue 91 and the fourth position is defined as residue 96. Sequence
highlighting scheme is the same as in (A).
(G) CDR L3 (cyan) interaction with loop D (orange) of superimposed gp120s shown for VRC01-class antibodies with Leu91LC (VRC-PG04d74; left), Phe91LC (VRC-
PG20d23 and 12A21d57; middle), and Tyr91LC (VRC01d45, VRC-CH31d0219 and 3BNC117d3; right).
(H) Relative decrease in affinity (vertical axis) of antibodies of the VRC01 class for gp120 (arranged horizontally) for wild-type (WT, white bars) and 91LC to Ala
substitutions (black bars).
(I) Relative decrease in affinity (vertical axis) of antibodies of the VRC01 class for gp120 (arranged horizontally) for WT (white bars) and Gln or Glu 96LC sub-
stitutions (black bars). See also Figure S2.
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Figure 4. Genetic Records for the Development of CDR L1 and CDR L3 Signatures for the VRC01 Class
(A) Light-chain antibodyomes of donors with VRC01-class antibodies. Top row shows that for each donor, light-chain sequences are plotted as a function of
sequence identity to an antibody of the VRC01 class identified in that donor (vertical axis) versus the sequence divergence from their assigned genomic V-gene
alleles. Color coding indicates the number of sequences. Middle row shows heat map display of the amino-acid usage at each position of the CDR L3, for all light
chains with 5-amino acid CDR L3s and greater than 15% germline divergence. Frequencies are colored from dark red (100% usage) to white (0%). Bottom row
shows sequences with 5-residue CDR L3s with sequences that contain amino acids with at least 10% usage are plotted as dots. Orange (or purple) indicates the
presence (or absence) of a CDR L1 deletion or mutation to glycine. Total numbers of sequences are listed in the corresponding colors.
(B) Maximum-likelihood phylogenetic trees of light-chain sequences with mature genetic CDR L3 signature as defined in (A), colored orange (or purple) for
sequences with (or without) CDR L1 signature. The nature of the CDR L1 signature is defined by ‘‘D’’ (deletion) or ‘‘GG’’ (mutation to glycine). See also Figure S3
and Table S2.
Immunity
Ontogeny of VRC01-Class Antibodiesrow), indicating that in some donors the CDR L3 of the initial re-
combinant either differs or contains amino acids with less than
20% frequency in the mature antibody population.252 Immunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc.To identify the sequence of the initial unmutated light chain, we
used the less restrictive structural signature (5-amino acid CDR
L3, hydrophobic residue 91LC, and glutamine or glutamic acid
Immunity
Ontogeny of VRC01-Class Antibodiesresidue 96LC). For all donors, except IAVI 23 for which the genetic
record was sparsely sampled, transcripts with the structural
signature were observed with low V-gene divergence. We
analyzed five sequences with the lowest V-gene divergence
from each donor to provide insight into germline recombinants
(Figures S3F and S3G). In donor RU3, an unmutated V-gene
with CDR L3 sequence QQYEF was identical in both initial re-
combinant and mature antibodies. In donor IAVI 57, sequences
with four of the mature genetic CDR L3 signature residues, but
a Leu at residue 90LC were identified, and in donor NIAID 45
and IAVI 74, several sequences with four of the mature genetic
CDR L3 signature residues were observed, but with a Thr at res-
idue 97LC. These results show that recombination produces a
CDR L3 with the elements critical for recognition: 5-amino acid
length, hydrophobic-91LC, and Glu or Gln-96LC. Somatic muta-
tion can then alter the CDR L3, but essential structurally-defined
elements are retained.
The use of a ‘‘mature genetic CDR L3 signature’’ to identify
likely VRC01-class antibody transcripts allowed us to follow
CDR L1 maturation in these sequences. We created and
analyzed phylogenetic trees for transcripts containing the
‘‘mature genetic CDR L3 signature’’—with the additional crite-
rion of whether a characteristic CDR L1 signature, either deletion
or mutation to glycine, was present or absent (Figure 4B). The
CDR L1 signature was observed to occur or not to occur in nearly
identical sequences throughout these phylogenetic trees, in all
donors except for IAVI 23, where the number of VRC01-class
transcripts was limited (Figure 4B). To compare functionality of
paired sequences, we synthesized light-chain pairs of donors
NIAID 45 and IAVI 57, reconstituted with heavy chains from
each of these donors, and observed virtually identical HIV-1
neutralization in those that expressed (Figures S3H–S3K; Table
S2D). Overall, these results indicate that the maturational alter-
ations required to produce the characteristic deletion or muta-
tion to glycine in CDR L1 might occur with minimal alteration
elsewhere; apparently, characteristic developmental features
might not always have substantial functional impact.
The genetic record for heavy chains of the VRC01 class in six
donors derives primarily from probe-identified monoclonal anti-
bodies, supplemented in donors NIAID 45 and IAVI 74 with
VRC01-class heavy-chain transcripts identified by a phyloge-
netic method (Scheid et al., 2011; Wu et al., 2011). We therefore
applied this phylogenetic method to donors RU 3 and IAVI 57
and identified 809 and 1632 VRC01-class transcripts, respec-
tively (Figures S3L and S3M), to supplement the genetic record
for these donors. To confirm functionality, we synthesized ten
diverse sequences from donor IAVI 57, reconstituted with the
12A21 light chain from donor IAVI 57, and confirmed HIV-1
neutralization (Tables S2B and S2E). As with previous analyses
(Scheid et al., 2011; Wu et al., 2011), VRC01-class transcripts
from these donors included diverse CDR H3 sequences, diverse
variable-region sequences, and highly skewed germline-gene
usage (Figure 5, Table S3A).
Overall, next-generation sequencing and associated bioinfor-
matics analyses provide a genetic record for developmental pro-
cesses of recombination and somatic mutation. For heavy chain,
recombination selects the IGHV1-2 gene, but D and J gene
choice does not appear to be restricted. For the light chain, the
genetic record shows that the signature CDR L3 of the VRC01class is generated primarily through recombination, which se-
lects elements critical for recognition, and that a characteristic
CDR L1 deletion or mutation to glycine generally appears later
in the maturation process, and then becomes common, often
interleaved on multiple phylogenetic branches.
Highly Skewed Germline V- and J-Gene Usage
The thousands of VRC01-class sequences now known in multi-
ple donors allows us to address questions such as which germ-
line antibody genes are compatible with VRC01-class recogni-
tion, and how frequently B cells with requisite class features
are produced by recombination. One source of insight into these
questions is through statistical analysis of genetic features,
where biases or skewing of gene usage can help to reveal mech-
anisms governing selection (Gilbert et al., 2011; Rolland et al.,
2012). Such skewing can derive from two dominant sources:
(1) functional selection, whereby only certain genes are compat-
ible with the VRC01 class, or (2) clonal amplification, due to there
being only a limited number of ancestor-B cells responsible for
the observed VRC01-class sequences in each donor.
For VRC01 class-heavy-chain sequences, preferential use of
the IGHV1-2 gene has been attributed to particular residues
(e.g., Trp50HC, Asn58HC, and Arg71HC) present in VH1-2 (West
et al., 2012). Not all VRC01-class antibodies, however, include
these residues (e.g., 12A21 has Leu50HC and VRC03 and VRC-
PG19 have Ser58HC), suggesting that the identified three-residue
signature is beneficial to recognition, but variation is permitted.
We incorporated the newly available sequence and structural in-
formation into a sequence and structural analyses of heavy-
chain characteristics of the VRC01 class. The analysis indicated
a number of additional signature residues (Figure S4A–S4G).
Some of these (e.g., Gly55HC) were common to a number of
germline genes, while others (e.g., Met or Leu69HC) were more
specific to VH1-2. In terms of heavy chain-J genes, we observed
all confirmed neutralizers of the VRC01 class to use IGHJ-genes
from four different JH-gene families, IGH-J1, IGH-J2, IGH-J4,
and IGH-J5. One requirement for the CDR H3 interaction for
VRC01-class members is the presence of a large hydrophobic
residue at position 100B (generally Trp, but Tyr and other hydro-
phobic residues are also observed) (Table S3A). These observa-
tions suggest that the heavy-chain-germline V-gene choice
derives from functional selection, whereas the J-gene choice
does not. Substantial skewing of J-gene usage in VRC01-class
antibodies would thus likely be related to clonal amplification.
The common use of IGVK3-20 and IGVK1-33 alleles in
different donors indicates light-chain V-gene preference or se-
lection. To understand the basis of this selection, we examine
the two regions of the light chain identified structurally as being
critical to recognition: the CDR L1 and CDR L3. With CDR L1,
we observed no substantial differences with respect to the
length or to the number of glycines in the CDR L1 region, be-
tween the light-chain-germline genes of VRC01-class antibodies
and the rest of the human variable lambda or kappa V-genes.
Moreover, a number of additional germlines were found to
exhibit short CDR L1s or a number of glycines, suggesting that
these CDR L1 features were not the dominant factors influencing
the compatibility of light-chain V-genes (Figures S5A and S5B).
With CDR L3, analysis of the C termini of the light-chain-germline
V-genes revealed only 38% to have a hydrophobic (e.g., Y, F,Immunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc. 253
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Figure 5. 454 Pyrosequencing-Derived Genetic Record of V- and J-Gene Usage for the VRC01 Class and Lineage Implications
Histograms of the assigned V-gene origin (top row) or J-gene origin (rows 2 and 3) are shown for VRC01-class transcripts identified fromdonor antibodyomeswith
the specific signatures provided in Figure 6B. Comparison of origin-gene assignments for VRC01-class transcripts (rows 1–3) versus those for all non-VRC01-
class transcripts provides a measure of the skewing of origin genes used by the VRC01 class. Observations from six donors define genes compatible with the
class (Figure 6B) and allow for an estimate of the skewing associated with functional selection. For skewing associated with clonal amplification from a limited
number of ancestor-B cells, we estimated probabilities (bottom row) that different numbers of clonal lineages could have given rise to the 454-observed VRC01-
class transcripts in each donor. Probability calculations based on both Bayesian and frequentist analyses are provided in Supplemental Experimental Pro-
cedures. See also Figure S4 and Table S3. (*Heavy chain J-gene distributions extracted from published antibody sequences for NIAID 45 and IAVI 74.)
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Ontogeny of VRC01-Class AntibodiesL, I, or V) at residue 91LC, and this might serve as a limiting factor
for germline selection (Figures S5C and S5D). Notably, only two
kappa genes, IGKV1-33 and IGKV3-20, had a guanine base
immediately after residue 91LC that could potentially facilitate
the emergence of the critical Glu96LC upon recombination (Fig-
ures S5C and S5D), and these appeared to be preferentially
observed as precursor light-chain V-genes for the VRC01 class.
Application of Bayesian and frequentist analyses to observed
light-chain V-genes indicates either 3–17 (Bayesian) or 3–12 (fre-
quentist) are compatible with the VRC01 class (Figures S4H–
S4J). For light-chain J-genes, we observed four different
J-genes (LJ2, KJ2, KJ3, and KJ5), indicating little preference,
despite stringent CDR L3 requirements.
Despite the compatibility of multiple light-chain V-gene and
J-genes and multiple heavy-chain J-genes within the VRC01
class of antibodies, next-generation sequencing in five donors
(RU 3, IAVI 23, NIAID 45, IAVI 57, and IAVI 74) indicated highly254 Immunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc.donor-specific gene usage. Indeed, in any given donor, all
VRC01-class antibodies appear to arise froma single set of origin
genes. The observation of a single V-gene and a single J-gene for
VRC01 class-light chains of each donor, and a single J-gene for
VRC01 class-heavy chains of each donor, an outcome that sta-
tistical analysis suggests is < 5% probable for more than a single
lineage in three donors (Figure 5; Tables S3B and S3C). The use
of a single JH, VL, and JL origin for VRC01-class antibodies in
each donor thus suggests that these antibodies derive from a
very limited—likely a single—ancestor-B cell.
VRC01-Class Ontogeny
The identification of VRC01-class antibodies in six donors
coupled to the determination of bioinformatics signatures for
the VRC01 class provides an unprecedented opportunity to
characterize the B cell ontogeny of a highly effective class of
HIV-1 neutralizing antibodies. This class-wide B cell ontogeny
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Figure 6. B Cell Ontogeny of the VRC01 Class of HIV-1-Neutralizing Antibodies
(A) CDR L1 signature as a function of V-gene divergence in VRC01-class transcripts (top row) or non-VRC01-class transcripts (bottom row). Additional data
provided in Table S4.
(B) Observed B cell ontogeny in donors RU3, IAVI 23, NIAID 45, IAVI 57, and IAVI 74. Frequency is calculated from observed versus total number of elements. For
example only 1 IGHV gene is observed (VH1-2) out of the 50 VH-germline alleles in each human. For IGKV or IGLV, frequentist analysis indicates 3–12 and
Bayesian analysis 3–17 out of a total of80 VL/K-germline alleles in each human. Specific recombination (to select the IGHV1-2 gene and a 5-amino acid CDR L3
with hydrophobic-Glu or Gln residue pair) and somatic mutation (to evolve heavy chain and CDR L1 signature) are observed in antibodies of the VRC01 class.
(C) Schematic of B cell ontogeny of the VRC01 class. See also Figure S5 and Table S4.
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Ontogeny of VRC01-Class Antibodiesanalysis includes antibody lineages from several HIV-1 donors
and thus differs from the analysis of individual B cell lineages
such as that carried out for HIV-1-neutralizing antibody CH103
in donor CH505 (Liao et al., 2013) or for hen egg white lyso-
zyme-recognizing antibodies (Li et al., 2003). The antibodyomics
analyses described here are from cross-sectional sampling; lon-gitudinal sampling should in principle allow a more complete
understanding of the development of antibody responses. None-
theless, our results show that it is possible to trace the B cell
ontogeny of the VRC01 class from unmutated B cell transcripts
to a clonal family of mature B cell transcripts corresponding to
neutralizing antibodies (Figure 6; Figures S5E and S5F). TheseImmunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc. 255
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Ontogeny of VRC01-Class Antibodiesresults include outcomes that appear stochastic, such as sub-
stantial sequence variation between class members, and out-
comes that appear deterministic, such as the remarkable similar-
ity in gp120 recognition or the development of the CDR L1
signature, which occurs in all six donors at similar levels of
V-gene divergence (Figure 6A; Tables S4A and S4B).
While the precise frequencies of antibody gene recombination
are dependent on a number of variables (Paul, 1999) including
the genes being combined, the frequency of required sequence
elements, and other factors (see for example, Feeney et al.,
2000), one can nonetheless provide a rough estimate of fre-
quency based on the assumption that each V, D, and J gene
has an equal probability of recombining. With this approxima-
tion, an estimate of the frequency of antibody recombinants
with VRC01-class characteristics is roughly 1 in 150,000: VH-
gene of IGHV1-2 (1 in 50), CDR L3 of 5 residues (1 in 100) with
hydrophobic at 91LC (1 in 3) and Gln or Glu at 96LC (1 in 10) (Fig-
ure 6B). If specific VL- or VK-genes are required (e.g., the 3 that
are observed among known VRC01 class antibodies out of the
total 77 known VL or VK genes, with an upper estimates of 12
or 17 as described in Figures S4K and S4L and Table S3B),
then this would reduce probability to be about 1 in roughly 1–4
million. These estimates suggest that, among the many millions
of naivemature B cells in each individual, a number with requisite
VRC01-class characteristic are produced each day. This
frequent occurrence of appropriate recombinants reflects the
relatively few specific genetic elements required for the class.
In general, selection from a small library can appear determin-
istic, whereas selection from a large library is more likely to
appear stochastic. Thus, in the case of the VRC01 class,
because of the limited number of structural solutions (for
example, the two solutions observed for CDR L1, Figures 3A–
3E), selection yields an apparently deterministic outcome.
Such outcomes might pertain in particular to antibodies that
require individual V-gene-encoded interactions such as the
VH1-2-derived VRC01 class or the VH1-69-derived influenza-
stem antibodies. By contrast, antibodies that recognize antigen
through CDR H3-encoded mechanisms might have many more
structural solutions, because of the far greater diversity of the
combinatorial V(D)J-derived library of sequences.
DISCUSSION
A detailed understanding of the B cell ontogeny for the VRC01
class provides a framework by which to define vaccine strate-
gies and to monitor the maturation process. Recent structure-
based immunogen design has created multimeric Env capable
of binding VRC01 class-germline precursors (Jardine et al.,
2013); although these achieve in vitro B cell activation, in vivo
activation has not yet been demonstrated. If immunization
were to stimulate naive mature B cells with VRC01-class charac-
teristics, then one should observe an increase in antibodies with
heavy chain derived from the VH1-2 germline and light chains
with 5-amino acid CDRL3, hydrophobic91LC andGlu or Gln96LC.
Such an increase should be apparent in the genetic record,
through use of the next-generation sequencing techniques.
Overall, our structural and sequencing findings define a repro-
ducible B cell ontogeny for a highly effective antibody class: the
VRC01 class. Such reproducibility enables class-specific strate-256 Immunity 39, 245–258, August 22, 2013 ª2013 Elsevier Inc.gies of elicitation, and the specific genetic signature defined here
allows for efficient detection.We note that the observation of one
or a very few ancestor-B cells for VRC01-class antibodies in
each donor parallels the observation of a single ‘‘founder’’ virus
that predominates for cases of HIV-1 infection involving mucosal
transmission (Keele et al., 2008). It will be interesting to see
whether alleviating blocks in VRC01 class-B cell development,
perhaps through immunizing with a modified gp120 or series of
gp120 immunogens with affinity to initial germline-recombinants
and maturation intermediates (Jardine et al., 2013; McGuire
et al., 2013) will allow multiple VRC01-class lineages to flourish
in the context of a vaccine.
EXPERIMENTAL PROCEDURES
Human Specimens
The peripheral blood mononuclear cells (PBMCs) of donor 45 (Li et al., 2007;
Wu et al., 2010), donor RU3 (Scheid et al., 2011), and donors 23, 57, and 74
from the international AIDS-vaccine initiative (IAVI) protocol G (Simek et al.,
2009; Walker et al., 2010) have been described previously. All human samples
were collected with informed consent under clinical protocols approved by the
appropriate institutional review board (IRB).
Isolation of Antibodies VRC-PG19 and VRC-PG20
Fluorescence-activated cell sorting of antigen-specific IgG+ B cells from
donor 23 PBMC and the amplification and cloning of immunoglobulin genes
were carried out with previously described protocols (Wu et al., 2010).
Expression and Purification of Antibodies and Fab Fragments
Expression plasmids for heavy and kappa chains were constructed as
described previously (Wu et al., 2010), as was the expression and purification
of antibody IgGs and preparation of Fab fragments.
ELISA
The binding of VRC-PG19 and VRC-PG20 to HIV-1 gp120 proteins and
competition with other antibodies were accessed with previously described
protocols (Wu et al., 2010).
Assessment of HIV-1 Neutralization
Neutralization by VRC-PG19 and VRC-PG20 was measured with single-
round-of-infection HIV-1 Env-pseudoviruses containing a luciferase reporter
gene to infect TZM-bl target cells that stably expresses high levels of CD4
and the coreceptors CCR5 andCXCR4 (Shu et al., 2007). Neutralization curves
were fit by nonlinear regression and the 50% and 80% inhibitory concentra-
tions (IC50 and IC80) were reported as the antibody concentration required to
inhibit infection by 50% and 80%, respectively.
Surface Plasmon Resonance
The effects of antibody light-chain CDR L3 mutations on binding constants to
gp120 were assessed by surface plasmon resonance on a Biacore T-200 in-
strument (GE Healthcare).
Crystallization, X-RayDataCollection, StructureDetermination, and
Refinement of VRC01-Class Antibodies inComplexwith HIV-1 gp120
The extended core (coreE) gp120 proteins from different HIV-1 stains were
constructed, and binary complexes of antibody Fab and HIV-1gp120 were pu-
rified and crystallized with protocols as described previously (Zhou et al.,
2010). X-ray diffraction data were integrated and scaled with the HKL2000
suite (Otwinowski and Minor, 1997). Crystal structures were solved by molec-
ular replacement with Phaser (McCoy et al., 2007) in the CCP4 Program Suite
(Collaborative Computational Project, 1994). Further refinements were carried
out with PHENIX (Adams et al., 2002). Startingwith torsion-angle simulated an-
nealing with slow cooling, iterative manual model building was carried out on
COOT (Emsley and Cowtan, 2004) with maps generated from combinations of
standard positional, individual B-factor, TLS refinement algorithms. Detailed
Immunity
Ontogeny of VRC01-Class Antibodiescrystallization conditions, structure solution, and refinement protocols are pro-
vided in Supplemental Experimental Procedures.
454 Pyrosequencing
454 pyrosequencing libraries of donor 45, donor RU3, and IAVI donors 23, 57,
and 74 were prepared, and 454 pyrosequencing of the PCR products were
performed as previously described (Wu et al., 2011).
Bioinformatics Analysis
Bioinformatics analyses of 454 pyrosequencing generated data were per-
formed with antibodyomics methods and consisted of two phases. In phase
one, the raw sequencing data were filtered, annotated, and processed with
a previously described pipeline (Wu et al., 2011) to improve sequence quality,
as well as to determine critical antibody characteristics such as V(D)J gene
origin, rate of somatic hypermuation, and complementarity-determining re-
gions (CDRs). In phase two, a suite of bioinformatics tools was used to analyze
the antibodyomes to identify light chains with specific signatures, to construct
phylogenetic trees, and to trace the evolution of sequence lineages of interest.
Details of these methods are described in Supplemental Experimental
Procedures.
Probability Analysis of Transcript Frequencies
Both frequentist and Bayesian analyses were used to analyze donor antibo-
dyomes with VRC01-class antibodyomes to understand the B cell ontogeny
of the VRC01 class. These analyses focused on defining the number of genetic
elements that contribute to the VRC01 class, as well as the number of indepen-
dent lineages that contribute to the VRC01 class in each donor. Details are
provided in Supplemental Experimental Procedures.
ACCESSION NUMBERS
Coordinates and structure factors for the nine antibody-HIV-1 gp120 complex
structures have been deposited with the Protein Data Bank under accession
codes 4JPV, 4JPW, 4LSP, 4LSQ, 4LSR, 4LSS, 4LST, 4LSU, and 4LSV. Raw
Roche 454 pyrosequencing data sets used in this study were deposited to
NCBI Sequence Read Archive (SRA) with accession number of SRA072279.
Verified neutralizing heavy- and light-chain variable-region sequences were
deposited to NCBI GenBank with accession numbers: KC848679–KC848710.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.immuni.2013.04.012.
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